This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Program at a Glance

Click on each day to access the program.

LEGEND: Basic Science Clinical Science Public Health

* program subject to change without notice.

 

7:00AM
2:00PM
3:45PM
4:15PM
6:00PM
Thursday, June 14
CAHN Symposium 7:00AM‑3:30PM | Room 715 7:00AM - 8:00AM: BREAKFAST & WELCOME

8:00AM - 10:00AM: SESSION I: CLINICAL PEARLS - MODERATOR: KATHY POLDRE

9:45AM - 10:00AM: BREAK

10:00AM - 12:30PM: SESSION II: PRACTICE AND RESEARCH - MODERATOR: CHERYL DALE

11:40AM - 12:30PM: LUNCH

12:30PM - 2:15PM: SESSION III: EVOLUTION AND INNOVATION - MODERATOR: COLINA YIM

2:05PM - 2:15PM: BREAK

2:15PM - 3:30PM: SESSION IV:  PANEL DISCUSSION - MODERATOR: LESLEY GALLAGHER
Registration 7:00AM‑6:30PM | Level 600 GHS 2018 Welcome Address & Plenary 1: WHO Elimination Targets | Exhibit Hall G Gottfried Hirnschall - Elmination targets: Rationale and WHO's role in helping countries get there
David Thomas - What tools are needed to generate the evidence - measuring success
Su Wang - Role of patient and community in the global response
Greg Dore - National elimination in a focused epidemic: Australia
Manal El-Sayed - National elimination in a generalized epidemic: Egypt
Afternoon Break 3:45PM‑4:15PM HCV Virology | Room 714 Thomas Baumert - HCV infection and entry

Jane McKeating - Physiological Regulation of HCV Replication

Ralf Bartenschlager - HCV virion production and assembly

Oral Abstracts
New Biomarkers & Endpoints in HBV | Room 716 Henry Chan - The value of HBsAg quantification in the natural history and treatment of HBV

Jean Michel Pawlotsky - Choosing the right endpoint for HBV treatment

Harry Janssen - New Biomarkers for HBV infection

Oral Abstracts
HEV Pathogenesis & Treatment | Rom 715 Shiv Sarin - HEV and emerging worldwide pathogen?

Heiner Wedemeyer - Treatment of HEV infection

Ken Sherman - HEV in immunocompromised patients

Oral Abstracts
Pan American Symposium | Room 701 Alexandra King (Canada, CASL) - Effective Viral Hepatitis Control Strategies in Canadian Indigenous Populations
Merv Thomas (Canada, CASL) - Community Readiness: A critical component to viral hepatitis control
Brian McMahon (US, AASLD) - Control of hepatitis B and its consequences in the Alaskan Native population
Jorge Mera (US, AASLD) - The Cherokee Elimination Project
Martin Tagle (Latin America, ALEH) - The challenge of viral hepatitis in the Andes
Raymundo Parana (Latin America, ALEH) - Addressing viral hepatitis - HBV & HDV - in the Amazon basin
Nick Walsh (US, WHO) - Efforts from PAHO to address viral hepatitis in Indigenous communities in the Americas
Exhibits, Posters & Welcome Reception 6:00PM‑8:00PM | Exhibit Hall F